The primary objective of pharmacological treatments for diabetes and obesity is to enhance and increase the release of GLP-1
Dosage Forms and Strengths Extended-release injectable suspension: 2 mg of exenatide per 0.85 mL suspension, in a pre-filled single-dose autoinjector
Supplementation of cystine restored mTORC1 signaling and treatment with rapamycin (a specific mTORC1 inhibitor) abolished the induction, providing evidence for the direct role of mTORC1 in the phosphorylation of p70S6K (T389) and S6 (S235/236)
All patient care is supervised by licensed physicians, and members receive ongoing medical oversight through our Care 360 support system
About AOD 9604/MOTS-c puts two metabolic peptides in a single vial, attacking fat from two angles
Unlike broad-spectrum treatments, targeted therapeutic peptides communicate directly with specific tissues: enamel matrix proteins, collagen-producing fibroblasts, muscle spindles, and immune mediators